- Home
- BJRI vs PRTA Comparison
BJRI vs PRTA Comparison
Compare BJRI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- PRTA
- Stock Information
- Founded
- BJRI 1978
- PRTA 2012
- Country
- BJRI United States
- PRTA Ireland
- Employees
- BJRI N/A
- PRTA N/A
- Industry
- BJRI Restaurants
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- PRTA Health Care
- Exchange
- BJRI Nasdaq
- PRTA Nasdaq
- Market Cap
- BJRI 797.9M
- PRTA 809.8M
- IPO Year
- BJRI 1996
- PRTA N/A
- Fundamental
- Price
- BJRI $33.75
- PRTA $13.75
- Analyst Decision
- BJRI Hold
- PRTA Buy
- Analyst Count
- BJRI 5
- PRTA 9
- Target Price
- BJRI $39.25
- PRTA $54.57
- AVG Volume (30 Days)
- BJRI 362.5K
- PRTA 382.6K
- Earning Date
- BJRI 05-01-2025
- PRTA 05-07-2025
- Dividend Yield
- BJRI N/A
- PRTA N/A
- EPS Growth
- BJRI N/A
- PRTA N/A
- EPS
- BJRI 0.70
- PRTA N/A
- Revenue
- BJRI $1,357,302,000.00
- PRTA $135,157,000.00
- Revenue This Year
- BJRI $5.58
- PRTA N/A
- Revenue Next Year
- BJRI $3.14
- PRTA $131.75
- P/E Ratio
- BJRI $49.21
- PRTA N/A
- Revenue Growth
- BJRI 1.81
- PRTA 47.92
- 52 Week Low
- BJRI $27.61
- PRTA $11.70
- 52 Week High
- BJRI $41.72
- PRTA $29.00
- Technical
- Relative Strength Index (RSI)
- BJRI 35.38
- PRTA 42.73
- Support Level
- BJRI $35.06
- PRTA $13.89
- Resistance Level
- BJRI $38.60
- PRTA $15.63
- Average True Range (ATR)
- BJRI 1.65
- PRTA 1.12
- MACD
- BJRI -0.33
- PRTA -0.09
- Stochastic Oscillator
- BJRI 0.50
- PRTA 10.17
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in one operating segment that is casual dining company-owned restaurants. It has geographic presence only in the United States of America.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).